A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients

Journal of Neurology Neurosurgery and Psychiatry

Volumn 61, Issue 3, 1996, Pages 265-269

  Burbaud, P ^a   Wiart, L ^a   Dubos, J L ^a   Gaujard, E ^a   Debelleix, X ^a   Joseph, P A ^a   Mazaux, J M ^a   Bioulac, B ^a   Barat, M ^a   Lagueny, A ^a  

^a HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

Botulinum toxin; Double blind trial; Foot spasticity

Indexed keywords

BOTULINUM TOXIN A;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FLEXOR MUSCLE; FOOT; GAIT; HEMIPARESIS; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPASTICITY; TIME; TREATMENT OUTCOME;

EID: 9544250392     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.61.3.265     Document Type: Article

References (29)

1. Young RR, Delwaide PJ. Drug therapy: spasticity (first of two parts). N Engl J Med 1981;304:28-33.
2. Young RR, Delwaide PJ. Drug therapy: spasticity (second of two parts). N Engl J Med 1981;304:96-99.
3. Penn RD, Savoy SM, Corcos D, et al. Intrathecal baclofen for severe spinal spasticity. N Eng J Med 1989;320: 1517-21.
4. Herz DA, Looman JE, Tiberio A, Ketterling K, Kreitsch RK, Colwill JC, Grin OD. The management of paralytic spasticity. Neurosurgery 1990;26:300-6.
5. Petrillo CR, Knoplech S. Phenol block of the tibial nerve: a long term follow up study. Int Disabil Studies 1988;10:97-100.
6. Privat JM, Privat C. Sectorial posterior rhizotomy for the treatment of spasticity in adults. In: Neurosurgery for spasticity. A multidisciplinary approach. New York: Springer Verlag, 1990:141-3.
7. American Academy of Neurology. Assessment: the clinical usefulness of botulinum toxin-A in treating neurological disorders. Neurology 1990;40:1332-6.
8. Clinical use of botulinum toxin A. National Institute of Health consensus development statement. Arch Neurol 1991;48:1294-7.
9. Das TK, Park DM. Botulinum toxin in treating spasticity. Br J Clin Pract 1989;43:401-2.
10. Snow BJ, Tsui JL, Bhatt MH, Varelas M, Hashimoto SA, Clane DB. Treatment of spasticity with botulinum toxin: a double blind study. Ann Neurol 1990;28:512-5.
11. Mémin B, Pollak P, Hommel M, Perret J. Traitement de la spasticité par la toxine botulique. Rev Neurol 1992;148: 212-4.
12. Hesse S, Friedrich H, Domasch C, Mauritz KH. Botulinum toxin therapy of upper-limb spasticity: preliminary results. Journal of Rehabilitation Science 1992;5:98-101.
13. Dunne JW, Heye N, Dunne SL. Treatment of chronic limb spasticity with botulinum toxin A. J Neurol Neurosurg Psychiatry 1995;58:232-5.
14. Dengler R, Neyer U, Wolfarth K, Bettig U, Janzic HH. Local botulinum toxin in the treatment of spastic drop foot. J Neurol 1992;239:375-8.
15. Konstanzer A, Ceballos-Bauman AO, Dressnandt J, Conrad B. Locale injektionsbehandlung mit Botulinum-toxin A bei schwerer arm-und bainspastic. Nervenartzt 1993;64:517-23.
16. Borg-Stein J, Pine ZM, Miller JR, Brin MF. Botulinum toxin for the treatment of spasticity in multiple sclerosis. Am J Phys Med Rehabil 1993;72:364-8.
17. Koman LA, Mooney JF, Smith B, Goodman A, Mulvaney T. Management of cerebral palsy with botulinum toxin-A: preliminary investigation. J Pediatr Orthop 1993;13: 489-95.
18. Hesse S, Lücke D, Malezic M, Bertelt C, Friedrich H, Gregoric M, Mauritz KH. Botulinum toxin treatment of lower limb extensor spasticity in chronic hemiparetic patients. J Neurol Neurosurg Psychiatry 1994;57:1321-4.
19. Cosgrove AP, Corry IS, Graham HK. Botulinum toxin in the management of the lower limb in cerebral palsy. Dev Med Child Neurol 1994;35:379-85.
20. Benecke R. Botulinum toxin for spasms and spasticity in the lower extremities. In: Jankovic J, Halett M, eds. Therapy with botulinum toxin. 1st ed. New York: Marcel Dekker, 1994:523-34.
21. Tsui JKC, O'Brian CF. Clinical trials for spasticity. In: Jankovic J, Halett M, eds. Therapy with botulinum toxin. 1st ed. New York: Marcel Dekker, 1994:557-65.
22. Bohannon RW, Smith MB. Interaliability of a modified Ashworth scale of muscle spasticity. Physical Therapy 1987;67:206-7.
23. Fugl-Meyer AR, Jösköl L, Leyman I, Olsson S, Speglind S. The post-stroke hemiplegic patients. Method for evaluation of physical performance. Scand J Rehabil Med 1975; 7:13-31.
24. Wade TT. Measure of motor impairment. In: Measurement in neurological rehabilitation. Oxford: Oxford University Press, 1992:154-7.
25. Hesse S, Berteldt C, Mauritz KH. Botulinum-toxin A for treatment of lower limb spasticity during a comprehensive rehabilitation program. Mov Disord 1995;10:391.
26. Poewe W, Wiessel J. Experience with botulinum toxin in cervical dystonia. In: Jankovic J, Halett M, eds. Therapy with botulinum toxin. 1st ed. New York: Marcel Dekker, 1994:267-78.
27. Zuber M, Sebald M, Bathien MD, de Recondo J, Rondot J. Botulinum antibodies in dystonic patients treated with type A botulinum toxin. Neurology 1993;43:1715-8.
28. Green P, Fahn S, Diamond B. Development of resistance to borulinum toxin type A in patients with torticolis. Mov Disord 1994;9:213-7.
29. Thilmann AF, Fellows SJ, Garms E. The mechanism of spastic muscle hypertonus. Brain 1991;114:233-44.